Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim announces results of duloxetine study

Boehringer Ingelheim announces results of duloxetine study

19th March 2007

Boehringer Ingelheim has announced the results of a clinical trial duloxetine at the 15th European Congress of Psychiatry held in Madrid. The study showed that a daily dose of 60 mg of the compounds reduces non-specific pain and emotional symptoms linked to depression.

The results showed a significant fall in average pain scores in patients administered with duloxetine, with a decrease of 45 per cent on an 11-point Likert scale, compared to a 29 per cent drop in those administered with a placebo.

Emotional symptoms measured with the Montgomery-Asberg Depression Rating Scale fell by 56 per cent, compared to a 39 per cent decease in those taking the placebo.

Duloxetine is a serotonin and norepinephrine reuptake inhibitor that is believed to affect pain perception through the increase of serotonin and noraderenaline in the central nervous system.

Professor Koen Demyttenaere, from the Department of Psychiatry at University Hospital, commented that traditional treatments of depression focus solely on the emotional symptoms of the disease, while pain and other physical symptoms can reduce the clarity of diagnosis and complicate patient management.

“In this study of depressed patients with at least moderate pain, duloxetine helped by significantly reducing both painful and emotional symptoms of depression and in decreasing the interference of pain with functioning.”

In May 2006, Boehringer Ingelheim presented pooled data from seven clinical trials showing that duloxetine reduced the symptoms of patients with depression to a greater extent than some other commonly prescribed medications.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.